NIX
LOE ApproachingNDATOPICALLOTIONPriority Review
Approved
Mar 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
NIX by GSK is clinical pharmacology: the pharmacokinetics (pk) of florfenicol (table 1) and flunixin (table 2) after subcutaneous injection of florfenicol and flunixin meglumine is described below: image of pharmacokinetic parameters table. Approved for bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and 3 more indications. First approved in 1986.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIX is a topical lotion combining florfenicol (antibiotic) and flunixin meglumine (NSAID) approved in 1986 for cattle. It treats bovine respiratory disease (BRD) caused by multiple pathogens including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, while controlling fever in beef and non-lactating dairy cattle. The dual mechanism provides both infection control and symptomatic relief.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling likely team contraction and shift toward defensive positioning or transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY: The pharmacokinetics (PK) of florfenicol (Table 1) and flunixin (Table 2) after subcutaneous injection of florfenicol and flunixin meglumine is described below: image of pharmacokinetic parameters table
Worked on NIX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.